Mark Newman, Author at Endocrine News

President's Viewpoint

Looking Back on Presidential Term: Highlights Include Support for Research Members, Progress on Obesity and Advocacy Fronts

As my presidential term winds down, I look back with pride and admiration at the sheer amount of exemplary programming that the Society provides for its members each year. I’d like to recount some highlights from the past 12 months as we prepare to change leadership at ENDO 2026, June 13-16, in Chicago, Ill. One...

Pharma Fridays

Pharma Friday – April 24, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...

Member News

Members in the News: Joseph T. Bass, MD, PhD, Elected to the AAAS

Endocrine Society member Joseph T. Bass, MD, PhD, has been elected to the American Academy of Arts & Sciences (AAAS). Bass is the Charles F. Kettering Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Ill. As a world leader in circadian biology and endocrinology, his creativity and insights as an endocrinologist...

Adrenal Investigator: Kotaro Sasaki, MD, PhD, details how his laboratory’s research is “poised to transform the field.”

Almost three years ago, Kotaro Sasaki, MD, PhD, was lauded as one of the Endocrine Society’s Early Investigator Award winners. Now he discusses his research that involves building a human adrenal gland from stem cells, the importance for scientists to attend ENDO, and why the process of publishing research can often prove challenging. What if...

Diabetes News and Research

Keto Diet May Improve Beta Cell Function in People with Type 2 Diabetes

People with type 2 diabetes on a high-fat, low-carbohydrate diet may have a better chance of reversing their diabetes than those on a low-fat diet, according to a small study published in the Journal of the Endocrine Society. Type 2 diabetes is a disease where the beta cells in the pancreas cannot secrete enough insulin...

President's Viewpoint

Early-Career Members Grow Careers Through Our Professional Development Programs

Spring in the northern hemisphere is a time of exploration, growth, and transition. That’s why I’m excited this month to highlight our Society programs that help rising clinicians and researchers explore, grow, and transition to careers in endocrinology. One of our newer programs is the Medical School Engagement Program (MSEP), which in April will welcome...

Pharma Fridays

Pharma Friday – April 10, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...

Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular...